Small caps round-up: Top Level Domain, Transense, SkyePharma

Top Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry operator of a new top level domain for London. If successful, Minds and Machines will provide the registry services for the dot London domain on behalf of DLD. The contract is for a seven year period, with a three-year renewal period.

Transense Technology has announced that it now has confirmed orders of $550,000 after its trading division, IntelliSAW, satisfied the conditions of a previous $275,000 order and received a second order of the same value. Under the second order, the IntelliSAW system will be deployed in Asia to provide performance data to enhance the robustness of the power grid. Significantly, industry experts have estimated that the market opportunity for sensors in Smart Grid applications to reach $85.5bn by 2014, the company said.

Drug developer SkyePharma has signed a second agreement to conduct a feasibility study with RespiVert, a small molecule drug discovery company owned by Janssen Biotech. The study will develop a dry power dosage form for a RespiVert compound, designed to treat patients with severe, chronic respiratory diseases such as asthma. "We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases," the firm said.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Angle, a technology commercialisation company, has announced that the clinical trial for Novocellus' IVF embryo viability product, EmbryoSure, has now begun. Novocellus is 92% owned by Angle. The firm has received approval from the Medicines and Healthcare products Regulatory Agency for the trial, and patient recruitment will begin this week. Four IVF clinics are paticipating in the trial with completion expected mid 2013. If successful, product launch is expected about a year later.

Music Festivals, has announced that songwriter and performer Leonard Cohen will be joining the line up at a new event to be produced by the Group called 'A Day at Hop Farm' to be held in September of this year at the same place as the Hop Farm Festival in Kent. "To get the opportunity to bring Leonard Cohen to the UK for his only appearance this year is a fantastic and humbling achievement. He is one of the undisputed forefathers of modern folk music and has honed his craft for nearly half a century. We are delighted he's decided to perform for us for what will be a truly memorable experience," the firm said.

UK gun manufactuter Manroy has won two new orders for its general purpose machine gun, worth a total of £0.4m, from two overseas customers. The firm said that although they were relatively small in value they were significant in terms of their strategic impact as it "confirms new and important export regions for the group".

NR